Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hCT-MSC in Newborns with HIE
NCT03635450Phase 1Completed
- Sponsor
- Joanne Kurtzberg
- Start
- Dec 2018
- Primary completion
- Jul 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of wharton's jelly mesenchymal stromal cells in hypoxic-ischemic encephalopathy (HIE) (2 cohorts), sponsored by Joanne Kurtzberg. Primary endpoints: Incidence of infusion reactions and Incidence of Infections post-infusion up to 2 Weeks. Started Dec 2018; status: completed.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT03635450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635450.